carbostyril has been researched along with Anemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, J; Chinta, VR; Gang, S; Gupta, U; Jeloka, T; Kanani, P; Kansagra, K; Khetan, P; Mavani, S; Rajanna, S; Reddy, SVK; Ruhela, V; Varade, D; Zala, K | 1 |
| Agrawal, D; Bandara Galahitiyawa, MC; De Silva, S; Jikki, P; Kanani, P; Kansagra, K; Koradia, P; Krishnan, J; Mavani, SB; Nazar, A; Parmar, D; Rajanna, S; Ramakrishna, C; Ruhela, V; Shah, H; Sharma, N; Shukla, V; Varade, D; Zala, K | 1 |
| Dhillon, S | 1 |
| Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, H; Patel, M; Patel, PR; Patel, V; Sutariya, B | 1 |
| Joshi, SN; Kansagra, KA; Nakrani, VB; Parmar, DV; Patel, HV; Patel, JC; Patel, NB; Shaikh, FA; Sharma, NS; Shelat, AD | 1 |
| Beuck, S; Schänzer, W; Thevis, M | 1 |
| Adjei, AA; Bruzek, L; Erlichman, C; Geyer, S; Hanson, LJ; Hillman, S; Kaufmann, SH; Marks, RS; Mauer, A; Vokes, EE; Wright, JJ | 1 |
| Chaffin, MK; Schmitz, DG | 1 |
| Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
| Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP | 1 |
| Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W | 1 |
| Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J | 1 |
| Gabrilove, JL | 1 |
3 review(s) available for carbostyril and Anemia
| Article | Year |
|---|---|
Desidustat: First Approval.
Topics: Adult; Anemia; Antineoplastic Agents; COVID-19 Drug Treatment; Erythropoietin; Humans; Hypoxia; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Quinolones; Renal Insufficiency, Chronic | 2022 |
Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.
Topics: Anemia; Animals; Cobalt; Doping in Sports; Erythropoiesis; GATA Transcription Factors; Glycine; Hematinics; Humans; Hydroxybenzoates; Hypoxia-Inducible Factor 1; Quinolones; Small Molecule Libraries; Substance Abuse Detection | 2012 |
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.
Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins | 2001 |
8 trial(s) available for carbostyril and Anemia
| Article | Year |
|---|---|
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).
Topics: Anemia; Epoetin Alfa; Erythropoietin; Hematinics; Hemoglobins; Humans; Quinolones; Recombinant Proteins; Renal Dialysis; Renal Insufficiency, Chronic | 2022 |
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).
Topics: Anemia; Darbepoetin alfa; Erythropoietin; Hematinics; Hemoglobins; Hepcidins; Humans; Quinolones; Renal Dialysis; Renal Insufficiency, Chronic; Vascular Endothelial Growth Factor A | 2022 |
Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erythropoiesis; Female; Hemoglobins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Middle Aged; Quinolones; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Anemia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Farnesyltranstransferase; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Neutropenia; Quinolones; Survival | 2003 |
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome | 2005 |
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting | 2000 |
2 other study(ies) available for carbostyril and Anemia
| Article | Year |
|---|---|
Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Topics: Anemia; Animals; Down-Regulation; Erythropoiesis; Erythropoietin; Female; Hepcidins; Inflammation; Iron; Liver; Male; Mice, Inbred BALB C; Prolyl-Hydroxylase Inhibitors; Quinolones; Rats, Inbred Lew; Reticulocyte Count | 2019 |
What is your diagnosis? Halicephalobus gingivalis.
Topics: Anemia; Animals; Antinematodal Agents; Enrofloxacin; Equidae; Female; Fluoroquinolones; Hematuria; Ivermectin; Kidney; Quinolones; Rhabditida; Rhabditida Infections; Treatment Outcome; Ultrasonography | 2004 |